Further investigation of oncogenic and tumor suppressive pathways in murine T-ALL models, including GATA3 and TCF1/LEF1, and their application to human leukemia may identify novel targets that alone, or in combination with other targets, will have fewer side effects without sacrificing anti-leukemia efficacy. This evidence concerns the gene TCF7 and leukemia.